[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study - Hofman, M S; Violet, J; Hicks, R J (Lancet Oncol, 2018)